Cargando…
Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin
Bullous pemphigoid (BP) is the most common autoimmune bullous skin disease that affects primarily patients older than 60 years. The majority of BP cases are spontaneous, but BP can also be triggered by certain drugs’ exposures. Since 2011, a growing number of observations has been reporting cases of...
Autores principales: | Chouchane, Karim, Di Zenzo, Giovanni, Pitocco, Dario, Calabrese, Laura, De Simone, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691092/ https://www.ncbi.nlm.nih.gov/pubmed/34930319 http://dx.doi.org/10.1186/s12967-021-03192-8 |
Ejemplares similares
-
Bullous Pemphigoid: Trigger and Predisposing Factors
por: Moro, Francesco, et al.
Publicado: (2020) -
The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets
por: Maglie, Roberto, et al.
Publicado: (2023) -
New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update
por: Genovese, Giovanni, et al.
Publicado: (2019) -
Bullous Pemphigoid and Other Pemphigoid Dermatoses
por: Pratasava, Valeryia, et al.
Publicado: (2021) -
IgE autoantibodies in serum and skin of non‐bullous and bullous pemphigoid patients
por: Lamberts, A., et al.
Publicado: (2020)